What is the stock symbol for Kailera Therapeutics?
Kailera Therapeutics, Inc. trades on the NASDAQ Global Select Market under the official stock ticker symbol KLRA. As a clinical-stage biopharmaceutical enterprise dedicated to developing innovative therapeutic solutions for obesity and metabolic diseases, the company utilizes this designated exchange code to manage its public market equity presence, investor relations, and capital market communications following its corporate transition.
Related FAQs
Kailera Therapeutics is principally located in Waltham, Massachusetts, within the thriving life sciences and biotechnology hub of the Boston metropolitan area.
Initial public offerings associated with specialized corporate entities, emerging biotechnology pioneers, or industrial firms operating under specific regional designations like Kailera involve rigorous book-building processes designed to raise subst...
Kailera Therapeutics, Inc. has its corporate headquarters located in Waltham, Massachusetts, United States.
Public offerings involving clinical-stage biopharmaceutical assets or corporate entities associated with Kailera therapeutics involve structured equity financing rounds designed to fund ongoing drug development programs.
Equity research projections and early-stage valuation frameworks targeting Kailera Therapeutics focus on its clinical-stage biotechnology pipeline addressing obesity and metabolic diseases.
Kailera Therapeutics is an advanced clinical-stage biopharmaceutical company focused entirely on developing a diversified pipeline of innovative treatments for obesity and metabolic diseases.
A single common share of Kakao Corp. trades at approximately 36,200 South Korean won (KRW) on the Korea Exchange, supported by a total corporate market capitalization exceeding 15.8 trillion won.
Kailera Therapeutics Inc. officially completed its initial public offering and became a publicly traded biopharmaceutical company on April 16, 2026, listing its shares on the NASDAQ Global Market under the ticker symbol KLRA.
Kailera Therapeutics stands out in the biopharmaceutical sector as a clinical-stage enterprise singularly focused on advancing an innovative, diversified portfolio of next-generation therapies designed to treat obesity and related metabolic condition...
Akero Therapeutics, Inc.
The technical term Kailera refers to a specialized networking software utility and client-server architecture designed primarily to enable netplay capabilities for emulated retro video games.
Kailera Therapeutics looks toward an encouraging future as an advanced clinical-stage biotechnology company focused on next-generation obesity care and metabolic disease treatments.
Companies frequently evaluate initial public offering market conditions before listing their common shares on major public stock exchanges.
Kailera Therapeutics operates as a publicly traded biopharmaceutical enterprise following its initial public offering on the NASDAQ stock exchange under the ticker symbol KLRA.
Kailera Therapeutics is an advanced clinical-stage biotechnology company that focuses its therapeutic pipeline primarily on the treatment and management of obesity, overweight conditions, and related metabolic complications.
China's National Medical Products Administration approved ecnoglutide (marketed locally as Xianweiying), developed by Sciwind Biosciences and commercialized in partnership with Pfizer, for chronic weight management in adults with overweight or obesit...
Kailera Therapeutics is an advanced clinical-stage biotechnology company focused on the development of innovative therapies for the treatment of obesity and related metabolic conditions.
KBR, Inc. is a prominent global technology and engineering solutions company providing professional services, scientific research, and project execution for government and commercial clients in aerospace, defense, and energy sectors.
The largest venture-backed biotechnology initial public offering in history was achieved by Parabilis Medicines, formerly known as FogPharma, which secured an upsized $670 million public market debut on the Nasdaq Global Select Market.
Karine Hagen is directly related to Torstein Hagen as his daughter.
Kailera Therapeutics Inc. successfully completed its initial public offering on April 16, 2026, pricing its shares at sixteen dollars each and trading under the ticker symbol KLRA on the NASDAQ exchange.
Investors residing in the United States who want to purchase shares of Kioxia Holdings Corporation, a major global memory and semiconductor manufacturer, must navigate international accessibility constraints since the company's primary public listing...
Kailera Therapeutics maintains full status as a publicly traded corporation, with its common shares listed and actively traded on the NASDAQ exchange.